The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Open accessAbstract
Expression of the receptor tyrosine kinase c-MET (MET, mesenchymal-epithelial transition factor) in many cancers, and its participation in multiple signal transduction pathways involved in malignant tumor growth, suggest a wide therapeutic potential for MET inhibition in human cancer. Here we describe the discovery and early clinical development of ARQ 197, a novel, selective, non–ATP-competitive inhibitor of MET. Phase I studies demonstrate that ARQ 197 has a predictable pharmacokinetics and favorable safety profile, making it a potentially ideal partner for combination with cytotoxic chemotherapies and targeted anticancer agents. Results from phase I and phase II trials demonstrate preliminary evidence of anticancer activity. New data from a global phase II randomized trial comparing a combination of ARQ 197 plus erlotinib with erlotinib/placebo, in endothelial growth factor receptor inhibitor-naïve patients with locally advanced/metastatic non–small cell lung cancer, demonstrate improvement in progression-free and overall survival with combined therapy. Results were especially pronounced for patients with non–squamous lung cancer histologies, and in particular molecularly defined subgroups including KRAS mutations. These and other data from ARQ 197 clinical trials in hepatocellular, germ-cell, pancreatic (in combination with gemcitabine), and colorectal (in combination with cetuximab and irinotecan) cancers further highlight the potential role of ARQ 197 in existing and emerging anticancer therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tivantinib is a selective oral MET inhibitor that has been used in monotherapy and combination therapy for solid tumors, including mCRC [188].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase
Birchmeier, C., & Gherardi, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01359-2 · Cited by 597
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Furge, K. A., Zhang, Y.-W., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203859 · Cited by 410
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J.-H., Han, S.-U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 329
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
Research works printed but not linked: 14
- Gu, 2009, Inhibition of HGF/c-Met pathway by ARQ 197: characterization of pharmacodynamic markers in vitro and in vivo
- Li, 2007, Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met inhibitor, in multiple xenograft models
- Savage, 2009, In vitro ADME Properties of ARQ-197. Comparison to in vivo data
- Santoro, 2010, A Phase Ib safety trial of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC)
- Rosen, 2007, Phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor
- Adjei, 2010, A Phase 1 dose-escalation trial of the c-MET inhibitor ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors
- Goldman, 2009, Phase I dose escalation trial (ARQ 197–111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib
- Santoro, 2010, Preliminary results from ARQ 197–144: a phase 1b safety trial evaluating ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC)
- Wagner, 2009, Preliminary results from a Phase 2 study of ARQ 197 in patients with microphthalmia transcription factor family (MiT) associated tumors
- ARQ 197 for subjects with relapsed or refractory germ cell tumors
- Camacho, 2010, A phase 1b dose-escalation trial evaluating ARQ 197 administered in combination with gemcitabine to patients with advanced solid tumors
- Schiller, 2010, Results from ARQ 197–209: a global randomized placebo-controlled Phase 2 clinical trial comparing erlotinib plus ARQ 197 to erlotinib plus placebo in previously treated EGFR-inhibitor naive patients with locally advanced or metastatic non-small cell lung cancer
- Sequist, 2010, Final results from ARQ 197–209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinb plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
- ARQ 197 in combination with chemotherapy in patients with metastatic colorectal cancer
Cited by
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Self-citation
Metadata
- Authors
- Adjei, A. A., Schwartz, B., & Garmey, E.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Arqule (United States) (US)
- Corresponding author
- Adjei, Alex A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-31
- Volume
- 16
- Issue
- 6
- Pages
- 788-799
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3228218
- OpenAlex
- W2120107140
- Cited by
- 73
- References
- 34
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 12 · 2013: 12 · 2012: 8
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- ARQ 197, MET inhibitors, non-ATP-competitive inhibitors, c-Met, non-small cell lung cancer, KRAS mutation, progression-free survival, hepatocellular carcinoma, germ cell tumors, pancreatic cancer, colorectal cancer, cetuximab, irinotecan, combination chemotherapy, pharmacokinetics, drug safety
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Irinotecan, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Dose-Response Relationship, Drug, Enzyme Inhibitors, Humans, Neoplasms, Pyrrolidinones, Quinazolines, Quinolines, Randomized Controlled Trials as Topic, Hepatocyte Growth Factor, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Receptors, Growth Factor, Proto-Oncogene Proteins c-met, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. https://app.cochat.ai/papers/10.1634/theoncologist.2010-0380
- The paper
- Adjei, A. A., Schwartz, B., & Garmey, E. (2011). Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. The Oncologist. https://doi.org/10.1634/theoncologist.2010-0380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.